Genedrive Regulatory News (GDR)

Epistem Holdings Plc ("Epistem" or the "Company")

Directors' Shareholdings

Epistem today provides an update regarding the Company's share investment plan, details of which were announced on 13 July 2009.

As a result of the subscription for Partnership Shares and the award of Matching Shares, executive Directors, Matthew Walls, Dr Catherine Booth, John Rylands and Dr Allan Brown each increased their beneficial interests in the Company by 450 ordinary shares of 1.5p each. These shares were acquired on 28 January 2015, 27 February 2015 and 27 March 2015 at prices of 273p, 260p and 225p respectively.

Following these transactions, the current beneficial interests of the executive Directors are set out below:

Ordinary Shares %

Matthew Walls 12,820 0.13%

Dr Catherine Booth 987,175 9.87%

John Rylands 197,073 1.97%

Dr Allan Brown 1,761 0.01%

Epistem further announces that it was informed on 2 April 2014 that, on that day, Dr Catherine Booth transferred 2,983 ordinary shares of 1.5 pence each to her Self Invested Personal Pension fund at a price of 225p Following this transaction, Dr. Catherine Booth's beneficial interest remains unchanged at 987,175 ordinary shares representing 9.87% of the Company's issued share capital.

For further details please contact:

Epistem Holdings Plc

Matthew Walls: Chief Executive Officer ++44 (0)161 606 7258

John Rylands: Finance Director

Peel Hunt LLP

James Steel ++44 (0)207 418 8900

Clare Terlouw

Walbrook PR

Mike Wort ++44 (0)207 933 8780

Anna Dunphy

Please see http://www.epistem.co.ukfor additional information.